New RSV vaccine trial targets younger High-Risk adults in china

NCT ID NCT07220109

Ongoing ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests a single dose of an experimental RSV vaccine in Chinese adults aged 18 to 59 who have health conditions that raise their risk for severe RSV disease. Researchers will compare their immune response to that of older adults (60+) from a previous study. The trial also monitors safety and side effects. About 750 participants will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Beijing, Beijing Municipality, 100049, China
GSK Investigational Site

Xiangtan, Hunan, 411228, China
GSK Investigational Site

Nanjing, Jiangsu, 211112, China
GSK Investigational Site

Chengdu, Sichuan, 611130, China
GSK Investigational Site

Chengdu, 610072, China
GSK Investigational Site

Chongqing, 400030, China
GSK Investigational Site

Chongqing, 401336, China
GSK Investigational Site

Guangzhou, 510180, China
GSK Investigational Site

Guangzhou, 510220, China
GSK Investigational Site

Jiujiang, China
GSK Investigational Site

Kunming, 650032, China
GSK Investigational Site

Nanning, 530000, China
GSK Investigational Site

Shanghai, 200000, China
GSK Investigational Site

Shanghai, 200040, China
GSK Investigational Site

Zhuhai, 519099, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.